AT-11 FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM

AIM: The treatment of recurrent glioblastoma remains an open issue and the role of BEV has been largely debated since only few data compared this agent with the standard agents. METHODS: A multicenter, open-label, randomized (2:1), non-comparative phase II study (EudraCT:2011-001363-46; AVAREG-ML257...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Fabi, Alessandra, Caserta, Claudia, Clavarezza, Matteo, Maiello, Evaristo, Cartenì, Giacomo, Rosti, Giovanni, Eoli, Marica, Lombardi, Giuseppe, Monteforte, Marta, Agati, Raffaele, Eusebi, Vincenzo, Galli, Anna, Doria, Simona, Franceschi, Enrico
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217788/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados